Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
- Conditions
- Hypoactive Sexual Desire Disorder
- Interventions
- Drug: Placebo Vaginal Insert
- Registration Number
- NCT03287232
- Lead Sponsor
- EndoCeutics Inc.
- Brief Summary
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 653
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Vaginal Insert - Prasterone Prasterone 6.5 mg (0.50%) Vaginal Insert -
- Primary Outcome Measures
Name Time Method Sexual desire 28 weeks Change from Baseline in sexual desire evaluated by the FSFI desire domain (Questions 1 \& 2).
Distress from low sexual desire 28 weeks Change from Baseline in distress from low sexual desire evaluated by question 13 of FSDS-DAO.
- Secondary Outcome Measures
Name Time Method Satisfying sexual events (SSEs) 28 weeks Change from Baseline in the number of SSEs from a daily log of sexual activity.
Trial Locations
- Locations (69)
Endoceutics site # 106
🇺🇸Huntsville, Alabama, United States
Endoceutics site # 104
🇺🇸Mobile, Alabama, United States
Endoceutics site # 117
🇺🇸Tucson, Arizona, United States
Endoceutics site # 108
🇺🇸Berkeley, California, United States
Endoceutics site # 121
🇺🇸Los Alamitos, California, United States
Endoceutics site #128
🇺🇸Los Angeles, California, United States
Endoceutics site # 30
🇺🇸San Diego, California, United States
Endoceutics site # 17
🇺🇸San Diego, California, United States
Endoceutics site # 36
🇺🇸Denver, Colorado, United States
Endoceutics site # 52
🇺🇸Denver, Colorado, United States
Scroll for more (59 remaining)Endoceutics site # 106🇺🇸Huntsville, Alabama, United States